Myriad Genetics, Inc. announced updates to its agreement with Illumina Inc. Myriad?s gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina?s updated research assay, TruSight? Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product.
As a result, a broad array of cancer types will receive GIS results and their HRD status. Combining Myriad?s HRD technology, which is used in MyChoice® CDx tumor-based test, with Illumina?s expertise in comprehensive genomic profiling will enable Myriad to broaden clinical research opportunities and potentially drive CDx development for HRD-based therapies across multiple potential tumor types. Broad availability of data and the Myriad GIS platform may help drive disease-site indication expansion and potential companion diagnostic product development beyond ovarian cancer.
Myriad?s MyChoice CDx is the most comprehensive homologous recombination deficiency (HRD) test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The MyChoice test [6] comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions).